Rho-dependent kinases ROCK I and ROCK II; vascular endothelial growth factor; retinal neovascularization; angiogenesis; endothelial signaling ANGIOGENESIS, the formation of blood vessels from preexisting ones, is a crucial process during embryonic development and in a number of pathological conditions. Angiogenesis is regulated by vascular-specific growth factors that induce complex intracellular signaling cascades activating endothelial cells (6) . VEGF is a growth factor inducing several angiogenesis-related endothelial functions, including migration and proliferation (6) . VEGF-receptor activation triggers several downstream signaling cascades, such as the extracellular signal-regulated kinase (ERK) 1/2 pathway (14) , the serine/threonine kinase Akt with subsequent nitric oxide release (4, 12, 13) , and the small GTPases Rho (19, 27) . Recent studies have suggested that VEGF-driven endothelial migration and angiogenesis require activation of the monomeric GTPase RhoA (19, 27) and that inhibition of RhoA disrupts tube formation in threedimensional matrixes (8, 16, 22) . Molecularly, GTP-bound RhoA activates the serine/threonine kinases ROCK I and ROCK II (7, 11) , which in turn promote stabilization of F-actin, phosphorylation of regulatory myosin light chain and an increase in contractility, processes involved in cell migration and metastasis (2, 21) . Other downstream targets of the GTPase RhoA are nonkinases (e.g., Rhophilin, Rhotekin, p140Dia) and lipid kinases (e.g., Citron kinase, PRK1, PIP5K, PLD), indicating that GTP-bound RhoA controls diverse pathways (2) .
Pharmacological inhibition of ROCK I/II has been pursued clinically in patients with coronary artery disease reporting a significant improvement of flow-mediated endothelium-dependent vasodilation that is likely mediated by the restoration of nitric oxide bioavailability in treated patients (20) . Yet, the molecular mechanisms on endothelial cells have not been unraveled even though recent data suggest increased expression and activity of endothelial nitric oxide synthase (eNOS) following Rho-dependent kinase inhibition (18) . The function of the serine/threonine kinases ROCK I and ROCK II during angiogenesis and vascular remodeling has been studied with contradictory results using the relatively unspecific ROCK I/II inhibitor Y-27632 (23) . Some reports have suggested an inhibitory role of pharmacological ROCK I/II inhibition on endothelial migration and capillary-like tube formation (24) . In contrast, the same and other reports have also demonstrated a stimulatory effect of ROCK I/II inhibition on capillary-like sprout formation and tube stability (17, 24) .
The present study was aimed at investigating the function of the Rho-dependent kinases ROCK I and ROCK II in angiogenesis. Employing a combination of cellular and biochemical approaches, we demonstrate that inhibition of ROCK I/II by the specific inhibitor H-1152 (10) activates angiogenesis in the oxygen-induced retinal neovascularization assay in vivo. This enhanced angiogenic response by H-1152, however, was blocked by the VEGF-receptor antagonist PTK787/ ZK222584 (PTK/ZK). Correspondingly, inhibition of the Rho-dependent kinases ROCK I/II using H-1152 and expression silencing of ROCK I/II by specific small-interfering RNAs (siRNAs) in endothelial cells activates VEGF-driven in-gel sprouting angiogenesis. Molecularly, ROCK I/II inhibition activates VEGF-receptor kinase insert domain receptor (KDR) and ERK1/2 phosphorylation in endothelial cells. Collectively, these data indicate that ROCK I and ROCK II act as negative regulators of angiogenesis in vivo and in vitro, validating ROCK I/II as attractive targets for the therapeutic manipulation of angiogenesis.
MATERIALS AND METHODS
Antibodies, growth factors, drugs, and siRNA. The following antibodies were used for this study: mouse anti-KDR 3G2 antibody (Tumor Biology Center Freiburg), mouse anti-phosphotyrosine antibody PY99 (Santa Cruz Biotechnology), rabbit anti-ERK1/2 antibody K-23 (Santa Cruz Biotechnology), mouse anti-phosphorylated (p) ERK1/2 antibody E-4 (Santa Cruz Biotechnology), rabbit anti-ROCK I antibody H-85 (Santa Cruz Biotechnology), goat anti-actin I-19 (Santa Cruz Biotechnology), rabbit anti-ROCK II antibody H-85 (Santa Cruz Biotechnology), and horseradish peroxidase-conjugated antibodies (DAKO). Recombinant VEGF was purchased from R&D Systems. Human umbilical vein endothelial cells (HUVEC) were cultured as recently described (19) . ROCK I/II inhibitor H-1152 (10) (Calbiochem) and Bayer/Schering codeveloped VEGF-receptor antagonist PTK/ZK (25) were dissolved in dimethyl sulfoxide (DMSO). The following validated ROCK I/II-specific siRNA molecules were used: ON-TARGET PLUS siRNA human ROCK I (ID: L-003536-00; Dharmacon); ON-TARGET PLUS siRNA human ROCK II (ID: L-004610-00; Dharmacon), and validated nontargeting negative control no. 1 siRNA (Ambion).
Oxygen-induced retinopathy model. The oxygen-induced retinopathy (OIR) mouse model was used to analyze the angiogenic potential of the ROCK I/II inhibitor H-1152 in vivo. At postnatal day 7, newborn mice were exposed to 75% oxygen for 5 days with their nursing mothers, and subsequently returned to room air (9) . All animals were weighted and randomly divided into four groups (DMSO, H-1152, H-1152 ϩ PTK/ZK, and PTK/ZK) (each group at least n ϭ 6). H-1152 (3 mg/kg body wt) and PTK/ZK (50 mg/kg body wt) were resolved in DMSO and once per day injected intraperitoneally for five consecutive days from postnatal day 12 to 16. At postnatal day 17, the animals were killed, and eyes were fixed in 4% formalin. Serial paraffin sections (6 m) were stained with periodic acid-Schiff and hematoxylin. The numbers of nuclei in preretinal neovascularizations were counted (5) . For statistical analysis, the one-way ANOVA with Bonferroni's posttest was used (10 sections/mouse). All animal experiments in this study were performed and approved according to institutional guidelines and the ARVO statement for the use of animals in ophthalmic and vision research.
In vitro angiogenesis assays. siRNA-transfected HUVEC (48 h after transfection) or untreated HUVEC were used as previously described (19) . For inhibitor experiments, spheroids were embedded together with the different inhibitors (H-1152 and PTK/ZK) followed by VEGF stimulation. Data were analyzed by Student's t-test (2-sided, unpaired). A P value of Ͻ0.05 was considered as statistically significant.
Western blotting. siRNA-transfected HUVEC or untreated HUVEC were starved overnight in 2.5% FCS. For inhibitor experiments, HUVEC were incubated for 30 min at 37°C, followed by incubation for 5 min with 100 M Na 3VO4 and 25 ng/ml VEGF for 5 min at 37°C (19) . The data are presented as means Ϯ SD. 
RESULTS

Inhibition of Rho-dependent kinases ROCK I/II enhances retinal neovascularization.
Pharmacological inhibition of ROCK I/II has been shown to improve endothelial function in patients with coronary artery disease (20) . To mechanistically study ROCK I/II kinases during endothelial cell activation and angiogenesis, we examined oxygen-induced retinal neovascularization in the OIR model (5) . Relative hypoxia in the OIR model between postnatal day 12 and 17 induces upregulation of VEGF and leads to the formation of neovascularizations protruding the inner limiting membrane toward the vitreous (1). Mice injected with H-1152 showed a 50% increase of preretinal new vessels compared with control mice (25.0 Ϯ 2.0 neovascular nuclei/single section in control mice and 37.5 Ϯ 4.6 in mice injected with H-1152, P Ͻ 0.05) (Fig. 1, A, B , C, and F). To further assess whether ROCK inhibitor H-1152 functions as a downstream modulator of VEGF-dependent signaling pathways, VEGF-receptor antagonist PTK/ZK (25) and H-1152 were used in combination ( Fig. 1 D and F) . Retinal neovascularizations were substantially inhibited by PTK/ZK alone (5 Ϯ 1.9) (Fig. 1, E and F) . In addition, administration of H-1152 and PTK/ZK (Fig. 1, D and F) did not reverse the retinal angiogenic response in the OIR model (4.8 Ϯ 1.9), suggesting ROCK I/II kinases as VEGF downstream effector molecules and negative regulators of hypoxia-induced angiogenesis.
Pharmacological inhibition of Rho-dependent kinases ROCK I/II activates VEGF-induced sprouting of endothelial cells.
To analyze the influence of ROCK I/II inhibition on angiogenic responses in more detail, we performed in-gel sprouting angiogenesis assays with HUVEC using increasing concentrations of the ROCK I/II inhibitor H-1152 (Fig. 2, A and B) . In presence of H-1152, HUVEC failed to induce stress fibers in response to VEGF stimulation (data no shown), but VEGFinduced in-gel sprouting angiogenesis was enhanced significantly (Fig. 2, A and B) . H-1152-treated HUVEC spheroids did not show morphological alterations in the absence of VEGF but formed larger lumenized capillary-like sprouts with more ramifications compared with VEGF stimulation alone (Fig.  2B) . The specificity of ROCK I/II inhibition on VEGF-induced functions was further confirmed in the spouting assay using H-1152 in the presence of the VEGF-receptor KDR inhibitor PTK/ZK. Cotreatment with H-1152 and PTK/ZK prevented the enhanced VEGF-induced endothelial sprouting after ROCK I/II inhibition (Fig. 2C) , establishing ROCK I/II kinases as VEGF downstream effector molecules in endothelial cells and during angiogenesis. 
siRNA-induced depletion of ROCK I/II in HUVEC increases VEGF-induced angiogenic sprouting.
To further prove the proangiogenic effect of the ROCK I/II inhibitor H-1152 on angiogenesis, expression of either ROCK I and/or ROCK II was specifically silenced by validated siRNAs in HUVEC (Fig. 3A) . siRNA-induced depletion of ROCK I, ROCK II, or both caused similar effects in angiogenic sprouting like treatment with H-1152. ROCK I-, ROCK II-, and ROCK I/II-silenced HUVEC spheroids showed an enhanced lumenized capillarylike sprout formation following VEGF stimulation compared with control siRNA-transfected HUVEC (Fig. 3, B and C) . Additionally, in ROCK I-, ROCK II-, and ROCK-I/II silenced endothelial cell VEGF-receptor KDR inhibition by PTK/ZK completely prevented the enhanced VEGF-induced endothelial sprouting (Fig. 3D) . preincubation of HUVEC with 0.1 M H-1152 increased the VEGF-driven but not baseline KDR activation (Fig. 4A) . Furthermore, treatment of HUVEC with different concentrations of H-1152 increased the VEGF-induced activation of ERK1/2 ( Fig. 4B ) (control 100% vs. control ϩ VEGF 360 Ϯ 150% vs. 0.1 M H-1152 ϩ VEGF 497 Ϯ 266% vs. 1 M H-1152 ϩ VEGF 642 Ϯ 396%). Importantly, a similar increase in ERK1/2 activation after H-1152 treatment (DMSO 100% vs. H-1152 293% vs. H-1152 ϩ PTK/ZK 157%) was also observed in cell lysates from mouse retinas (Fig. 1G) , strongly supporting these in vitro data. Like pharmacological ROCK I/II inhibition, depletion of either ROCK I, ROCK II, or both isoforms also increased the VEGF-induced ERK1/2 activation (Fig. 4C ) (control siRNA 100% vs. control siRNA ϩ VEGF 234 Ϯ 46% vs. ROCK I siRNA ϩ VEGF 290 Ϯ 62% vs. ROCK II siRNA ϩ VEGF 318 Ϯ 26% vs. ROCK I/II siRNA ϩ VEGF 481 Ϯ 118%). Yet, VEGF-driven activation of VEGF-receptor KDR in siRNA-silenced endothelial cells was not increased significantly, which reflects technical limitations because of long-term siRNA transfection and sophisticated receptor activation assays (data not shown). Taken together, the data demonstrate that inhibition of ROCK I/II activity enhances endothelial signaling, in-gel sprouting angiogenesis, and retinal neovascularization. The experiments consequently identify ROCK I/II as negative regulators of endothelial function and of VEGF-receptor signaling in endothelial cells.
Inhibition of endothelial ROCK I/II increases VEGF-in-
DISCUSSION
The data presented herein show that the ROCK I/II inhibitor H-1152 exhibits profound effects on vascular angiogenesis and provide several lines of evidences that the Rho-dependent kinases ROCK I and ROCK II are negative regulators of VEGF-induced angiogenic endothelial cell activation. This was substantiated experimentally by: 1) an enhancement of retinal neovascularization, sprouting angiogenesis, VEGF-receptor KDR phosphorylation, and ERK1/2 activation in endothelial cells after ROCK I/II inhibition using the pharmacological inhibitor H-1152, 2) a similar enhancement by siRNAinduced ROCK I/II depletion in endothelial cells, and 3) the sensitivity of the VEGF-driven enhancements to the VEGFreceptor KDR inhibitor PTK/ZK.
Pharmacological inhibition as well as expression silencing of ROCK I and ROCK II in endothelial cells increase VEGFdriven angiogenesis. H-1152 has high angiogenic potential in the OIR model in vivo, enhances VEGF-driven in-gel sprouting angiogenesis, and activates VEGF-driven activation of VEGF-receptor KDR and ERK1/2 in endothelial cells. Depletion of ROCK I/II in endothelial cells using specific siRNAs has similar effects. Taken together, these data indicate that inhibition of ROCK I/II in endothelial cells strongly activates VEGF-driven angiogenesis. VEGF induces specific angiogenesis-related endothelial functions, including migration, proliferation, nitric oxide release, and permeability (6) . These functions are mediated by different intracellular signaling cascades. The first step in all the cascades, however, is activation of the VEGF-receptor KDR, which can be monitored by its autophosphorylation. Our data provide evidence that already this crucial step is under control of the ROCK isoforms, since inhibition of ROCK I/II activity by H-1152 increased the phosphorylation state of the VEGF-stimulated but not the unstimulated KDR. Furthermore, increased neovascularization in the OIR model after ROCK I/II inhibition strongly supports these in vitro data, since the H-1152-driven increase in blood vessel growth was completely dependent on VEGF-receptor KDR activation. Therefore, it is likely that a negative feedback loop exists in which VEGF-induced ROCK I/II activation counteracts KDR activation. In line with this interpretation, overexpression of constitutive active ROCK in HUVEC downregulated expression of eNOS and inhibited formation of nitric oxide, suggesting that ROCK I/II negatively regulates nitric oxide release in endothelial cells (18) . Because VEGF regulates expression of eNOS and inducible nitric oxide synthase and activates nitric oxide release via VEGF-receptor KDR (13, 15) , the observations may be explained by a decreased sensitivity of the VEGF system after ROCK I/II activation. Nevertheless, the data available in the literature regarding the pharmacological inhibition of ROCK I/II report apparently conflicting results with respect to regulation of angiogenesis and rely mainly on the use of Y-27632 and fasudil. Even with the use of the same concentrations of Y-27632, negative (24) or positive (17) effects were reported on endothelial migration and sprouting. More interestingly, with respect to VEGFinduced capillary-like tube formation, Y-27632 induced, in the same assay, inhibitory effects on the tube length but stimulatory effects on the tube number (24) . In addition, fasudil has been described to inhibit angiogenesis (26) but improves endothelial function in patients (20) . Our data may shed some light on these discrepancies. From the used pharmacological inhibitors, only H-1152, which is believed to be one of the most specific ROCK inhibitors (3), exerted similar morphological and functional effects in all tested in vitro assays than the depletion of ROCK I/II by siRNA. In our assays, ROCK I/II inhibitors fasudil and Y-27632 exerted strong effects on HUVEC sprout morphology (unpublished data). This might be related to the known fact that these inhibitors are promiscuous with regard to the inhibition of other important kinases in signaling pathways. Within the used concentration ranges, for example, inhibition of protein kinase C-related kinases, p90 ribosomal S6 protein kinases, mitogen-and stress-activated protein kinases, and phosphorylase kinase have been described (3) . It is therefore likely that the observed differences between the used pharmacological inhibitors reflect these differences in kinase specificity.
In summary, our data identify the inhibition of ROCK I/II activity in endothelial cells as an interesting therapeutic target to enhance/promote angiogenesis. However, future research is needed to address the question whether more specific pharmacological inhibitors can optimize the use of such substances in therapy or if less specific inhibitors, which already have been proven for beneficial effects (20) , might be more useful because of their additional effects on other kinases.
